Insider transactions

EDGAR

MILESTONE PHARMACEUTICALS INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-20.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
13 transactions, 523,079 shares
Sum of shares × price per share: 1,176,157.46

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 56

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-06-10 Filed 2026-06-12Saik Andrew Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (77,000) — exercise price 1.22
Acquired (A)77,0000—77,000Direct (D) No
F1
  • F1 This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.
Open filing 0001616284-26-000002 Read from the filing’s XML Dispute this row
2026-06-10 Filed 2026-06-12Giles Lisa M. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (77,000) — exercise price 1.22
Acquired (A)77,0000—77,000Direct (D) No
F1
  • F1 This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.
Open filing 0001568850-26-000002 Read from the filing’s XML Dispute this row
2026-06-10 Filed 2026-06-12PAPA JOSEPH C Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (77,000) — exercise price 1.22
Acquired (A)77,0000—77,000Direct (D) No
F1
  • F1 This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.
Open filing 0001242215-26-000014 Read from the filing’s XML Dispute this row
2026-06-10 Filed 2026-06-12Duty Stuart Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (77,000) — exercise price 1.22
Acquired (A)77,0000—77,000Direct (D) No
F1
  • F1 This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.
Open filing 0001970274-26-000004 Read from the filing’s XML Dispute this row
2026-06-10 Filed 2026-06-12Fischer Seth H. Z. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (77,000) — exercise price 1.22
Acquired (A)77,0000—77,000Direct (D) No
F1
  • F1 This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.
Open filing 0001573553-26-000002 Read from the filing’s XML Dispute this row
2026-06-10 Filed 2026-06-12TOMSICEK MICHAEL JOHN Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (77,000) — exercise price 1.22
Acquired (A)77,0000—77,000Direct (D) No
F1
  • F1 This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.
Open filing 0001570392-26-000003 Read from the filing’s XML Dispute this row
2026-06-10 Filed 2026-06-12Wills Robert James Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (77,000) — exercise price 1.22
Acquired (A)77,0000—77,000Direct (D) No
F1
  • F1 This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.
Open filing 0001634189-26-000002 Read from the filing’s XML Dispute this row
2026-04-16 Filed 2026-04-20Oliveto Joseph Director · Officer: President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Shares
Disposed (D)36,5002.26
82,490

Derived: shares × price per share. Exact value 82490.00.

446,244Direct (D) Yes
F1, F2
  • F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25 to $2.28 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote.
Open filing 0001437782-26-000010 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-05Nelson Jeffrey Edward Officer: Chief Operating Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Shares (204,000) — exercise price 1.96
Acquired (A)204,0000—204,000Direct (D) No
F1, F2
  • F1 The exercise price on the initial filings was incorrectly stated.
  • F2 One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
Open filing 0001943112-26-000005 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-05Muller Lorenz Officer: Chief Commercial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Shares (204,000) — exercise price 1.96
Acquired (A)204,0000—204,000Direct (D) No
F1, F2
  • F1 The exercise price on the initial filings was incorrectly stated.
  • F2 One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
Open filing 0001771207-26-000005 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-05Bharucha David Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Shares (204,000) — exercise price 1.96
Acquired (A)204,0000—204,000Direct (D) No
F1, F2
  • F1 The exercise price on the initial filings was incorrectly stated.
  • F2 One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
Open filing 0001910985-26-000006 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-05Oliveto Joseph Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Shares (679,000) — exercise price 1.96
Acquired (A)679,0000—679,000Direct (D) No
F1, F2
  • F1 The exercise price on the initial filings was incorrectly stated.
  • F2 One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
Open filing 0001437782-26-000007 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-05Hasija Amit Officer: CFO EVP of Corp. Development
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Shares (204,000) — exercise price 1.96
Acquired (A)204,0000—204,000Direct (D) No
F1, F2
  • F1 The exercise price on the initial filings was incorrectly stated.
  • F2 One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
Open filing 0001787700-26-000005 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-04Muller Lorenz Officer: Chief Commercial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Shares (204,000) — exercise price 1.97
Acquired (A)204,0000—204,000Direct (D) No
F1
  • F1 One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
Open filing 0001771207-26-000004 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-04Muller Lorenz Officer: Chief Commercial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Unit — underlying Common Shares (136,000)
Acquired (A)136,0000—136,000Direct (D) No
F2, F3
  • F2 Each restricted stock unit represents a contingent right to receive one common share.
  • F3 One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of February 2, 2027, February 2, 2028, February 2, 2029 and February 2, 2030, subject to the Reporting Person continuing to provide service through each such date.
Open filing 0001771207-26-000004 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-04Bharucha David Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Shares (204,000) — exercise price 1.97
Acquired (A)204,0000—204,000Direct (D) No
F1
  • F1 One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
Open filing 0001910985-26-000005 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-04Bharucha David Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Unit — underlying Common Shares (136,000)
Acquired (A)136,0000—136,000Direct (D) No
F2, F3
  • F2 Each restricted stock unit represents a contingent right to receive one common share.
  • F3 One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of February 2, 2027, February 2, 2028, February 2, 2029 and February 2, 2030, subject to the Reporting Person continuing to provide service through each such date.
Open filing 0001910985-26-000005 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-04Nelson Jeffrey Edward Officer: Chief Operating Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Shares (204,000) — exercise price 1.97
Acquired (A)204,0000—204,000Direct (D) No
F1
  • F1 One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
Open filing 0001943112-26-000004 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-04Nelson Jeffrey Edward Officer: Chief Operating Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Unit — underlying Common Shares (136,000)
Acquired (A)136,0000—136,000Direct (D) No
F2, F3
  • F2 Each restricted stock unit represents a contingent right to receive one common share.
  • F3 One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of February 2, 2027, February 2, 2028, February 2, 2029 and February 2, 2030, subject to the Reporting Person continuing to provide service through each such date.
Open filing 0001943112-26-000004 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-04Hasija Amit Officer: CFO EVP of Corp. Development
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Shares (204,000) — exercise price 1.97
Acquired (A)204,0000—204,000Direct (D) No
F1
  • F1 One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
Open filing 0001787700-26-000004 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-04Hasija Amit Officer: CFO EVP of Corp. Development
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Unit — underlying Common Shares (136,000)
Acquired (A)136,0000—136,000Direct (D) No
F2, F3
  • F2 Each restricted stock unit represents a contingent right to receive one common share.
  • F3 One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of February 2, 2027, February 2, 2028, February 2, 2029 and February 2, 2030, subject to the Reporting Person continuing to provide service through each such date.
Open filing 0001787700-26-000004 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-04Oliveto Joseph Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Shares (679,000) — exercise price 1.97
Acquired (A)679,0000—679,000Direct (D) No
F1
  • F1 One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
Open filing 0001437782-26-000006 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-04Oliveto Joseph Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Unit — underlying Common Shares (453,000)
Acquired (A)453,0000—453,000Direct (D) No
F2, F3
  • F2 Each restricted stock unit represents a contingent right to receive one common share.
  • F3 One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of February 2, 2027, February 2, 2028, February 2, 2029 and February 2, 2030, subject to the Reporting Person continuing to provide service through each such date.
Open filing 0001437782-26-000006 Read from the filing’s XML Dispute this row
2026-01-26 Filed 2026-01-28Muller Lorenz Officer: Chief Commercial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Shares
Acquired (A)20,100——216,586Direct (D) No
F5
  • F5 Each RSU represents a contingent right to receive one common share.
Open filing 0001771207-26-000002 Read from the filing’s XML Dispute this row
2026-01-26 Filed 2026-01-28Muller Lorenz Officer: Chief Commercial Officer
S

Open market or private sale of non-derivative or derivative security

Common Shares
Disposed (D)11,1801.93
21,577.4

Derived: shares × price per share. Exact value 21577.40.

205,406Direct (D) No
F3, F4
  • F3 Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit (RSU) awards only, respectively.
  • F4 The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001771207-26-000002 Read from the filing’s XML Dispute this row
2026-01-26 Filed 2026-01-28Muller Lorenz Officer: Chief Commercial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Shares (20,100)
Disposed (D)20,1000—60,300Direct (D) No
F5, F7
  • F5 Each RSU represents a contingent right to receive one common share.
  • F7 One-fourth (1/4th) of the shares subject to the RSU award vested or will vest on each of January 26, 2026, January 26, 2027, January 26, 2028 and January 26, 2029, subject to the Reporting Person continuing to provide service through each such date.
Open filing 0001771207-26-000002 Read from the filing’s XML Dispute this row
2026-01-26 Filed 2026-01-28Oliveto Joseph Director · Officer: President and CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Shares
Acquired (A)66,600——517,267Direct (D) No
F5
  • F5 Each RSU represents a contingent right to receive one common share.
Open filing 0001437782-26-000004 Read from the filing’s XML Dispute this row
2026-01-26 Filed 2026-01-28Oliveto Joseph Director · Officer: President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Shares
Disposed (D)34,5231.93
66,629.39

Derived: shares × price per share. Exact value 66629.39.

482,744Direct (D) No
F3, F4
  • F3 Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit (RSU) awards only, respectively.
  • F4 The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001437782-26-000004 Read from the filing’s XML Dispute this row
2026-01-26 Filed 2026-01-28Oliveto Joseph Director · Officer: President and CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Shares (66,600)
Disposed (D)66,6000—199,800Direct (D) No
F5, F7
  • F5 Each RSU represents a contingent right to receive one common share.
  • F7 One-fourth (1/4th) of the shares subject to the RSU award vested or will vest on each of January 26, 2026, January 26, 2027, January 26, 2028 and January 26, 2029, subject to the Reporting Person continuing to provide service through each such date.
Open filing 0001437782-26-000004 Read from the filing’s XML Dispute this row
2026-01-26 Filed 2026-01-28Hasija Amit Officer: CFO EVP of Corp. Development
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Shares
Acquired (A)20,100——112,093Direct (D) No
F5
  • F5 Each RSU represents a contingent right to receive one common share.
Open filing 0001787700-26-000002 Read from the filing’s XML Dispute this row
2026-01-26 Filed 2026-01-28Hasija Amit Officer: CFO EVP of Corp. Development
S

Open market or private sale of non-derivative or derivative security

Common Shares
Disposed (D)12,2451.93
23,632.85

Derived: shares × price per share. Exact value 23632.85.

99,848Direct (D) No
F3, F4
  • F3 Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit (RSU) awards only, respectively.
  • F4 The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001787700-26-000002 Read from the filing’s XML Dispute this row
2026-01-26 Filed 2026-01-28Hasija Amit Officer: CFO EVP of Corp. Development
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Shares (20,100)
Disposed (D)20,1000—60,300Direct (D) No
F5, F7
  • F5 Each RSU represents a contingent right to receive one common share.
  • F7 One-fourth (1/4th) of the shares subject to the RSU award vested or will vest on each of January 26, 2026, January 26, 2027, January 26, 2028 and January 26, 2029, subject to the Reporting Person continuing to provide service through each such date.
Open filing 0001787700-26-000002 Read from the filing’s XML Dispute this row
2026-01-26 Filed 2026-01-28Bharucha David Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Shares
Acquired (A)20,100——125,426Direct (D) No
F5
  • F5 Each RSU represents a contingent right to receive one common share.
Open filing 0001910985-26-000003 Read from the filing’s XML Dispute this row
2026-01-26 Filed 2026-01-28Bharucha David Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Shares
Disposed (D)12,2451.93
23,632.85

Derived: shares × price per share. Exact value 23632.85.

113,181Direct (D) No
F3, F4
  • F3 Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit (RSU) awards only, respectively.
  • F4 The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001910985-26-000003 Read from the filing’s XML Dispute this row
2026-01-26 Filed 2026-01-28Bharucha David Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Shares (20,100)
Disposed (D)20,1000—60,300Direct (D) No
F5, F7
  • F5 Each RSU represents a contingent right to receive one common share.
  • F7 One-fourth (1/4th) of the shares subject to the RSU award vested or will vest on each of January 26, 2026, January 26, 2027, January 26, 2028 and January 26, 2029, subject to the Reporting Person continuing to provide service through each such date.
Open filing 0001910985-26-000003 Read from the filing’s XML Dispute this row
2026-01-26 Filed 2026-01-28Nelson Jeffrey Edward Officer: Chief Operating Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Shares
Acquired (A)20,100——62,093Direct (D) No
F5
  • F5 Each RSU represents a contingent right to receive one common share.
Open filing 0001943112-26-000002 Read from the filing’s XML Dispute this row
2026-01-26 Filed 2026-01-28Nelson Jeffrey Edward Officer: Chief Operating Officer
S

Open market or private sale of non-derivative or derivative security

Common Shares
Disposed (D)12,2451.93
23,632.85

Derived: shares × price per share. Exact value 23632.85.

49,848Direct (D) No
F3, F4
  • F3 Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit (RSU) awards only, respectively.
  • F4 The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001943112-26-000002 Read from the filing’s XML Dispute this row
2026-01-26 Filed 2026-01-28Nelson Jeffrey Edward Officer: Chief Operating Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Shares (20,100)
Disposed (D)20,1000—60,300Direct (D) No
F5, F7
  • F5 Each RSU represents a contingent right to receive one common share.
  • F7 One-fourth (1/4th) of the shares subject to the RSU award vested or will vest on each of January 26, 2026, January 26, 2027, January 26, 2028 and January 26, 2029, subject to the Reporting Person continuing to provide service through each such date.
Open filing 0001943112-26-000002 Read from the filing’s XML Dispute this row
2026-01-08 Filed 2026-01-09Oliveto Joseph Director · Officer: President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Shares
Disposed (D)43,0002.25
96,750

Derived: shares × price per share. Exact value 96750.00.

303,721Direct (D) Yes
F1, F2
  • F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25 to $2.265 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001437782-26-000002 Read from the filing’s XML Dispute this row
2026-01-07 Filed 2026-01-09Oliveto Joseph Director · Officer: President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Shares
Disposed (D)5002.25
1,125

Derived: shares × price per share. Exact value 1125.00.

346,721Direct (D) Yes
F1
  • F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.
Open filing 0001437782-26-000002 Read from the filing’s XML Dispute this row
2025-12-15 Filed 2026-01-28Muller Lorenz Officer: Chief Commercial Officer
S

Open market or private sale of non-derivative or derivative security

Common Shares
Disposed (D)53,5662.32
124,273.12

Derived: shares × price per share. Exact value 124273.12.

196,486Direct (D) No
F3, F4
  • F3 Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit (RSU) awards only, respectively.
  • F4 The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001771207-26-000002 Read from the filing’s XML Dispute this row
2025-12-15 Filed 2026-01-28Oliveto Joseph Director · Officer: President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Shares
Disposed (D)133,0542.32
308,685.28

Derived: shares × price per share. Exact value 308685.28.

450,667Direct (D) No
F3, F4
  • F3 Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit (RSU) awards only, respectively.
  • F4 The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001437782-26-000004 Read from the filing’s XML Dispute this row
2025-12-15 Filed 2026-01-28Hasija Amit Officer: CFO EVP of Corp. Development
S

Open market or private sale of non-derivative or derivative security

Common Shares
Disposed (D)58,0072.32
134,576.24

Derived: shares × price per share. Exact value 134576.24.

91,993Direct (D) No
F3, F4
  • F3 Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit (RSU) awards only, respectively.
  • F4 The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001787700-26-000002 Read from the filing’s XML Dispute this row
2025-12-15 Filed 2026-01-28Bharucha David Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Shares
Disposed (D)58,0072.32
134,576.24

Derived: shares × price per share. Exact value 134576.24.

105,326Direct (D) No
F3, F4
  • F3 Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit (RSU) awards only, respectively.
  • F4 The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001910985-26-000003 Read from the filing’s XML Dispute this row
2025-12-15 Filed 2026-01-28Nelson Jeffrey Edward Officer: Chief Operating Officer
S

Open market or private sale of non-derivative or derivative security

Common Shares
Disposed (D)58,0072.32
134,576.24

Derived: shares × price per share. Exact value 134576.24.

41,993Direct (D) No
F3, F4
  • F3 Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit (RSU) awards only, respectively.
  • F4 The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001943112-26-000002 Read from the filing’s XML Dispute this row
2025-12-12 Filed 2026-01-28Muller Lorenz Officer: Chief Commercial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Shares
Acquired (A)100,000——250,052Direct (D) No
F1, F2
  • F1 Represents a performance stock unit (PSU) award that vested upon the certification by the Compensation Committee of the Board of Directors of the Issuer that the U.S. Food and Drug Administration has provided a New Drug Application Approval Letter granting approval of Cardamyst (etripamil).
  • F2 Each PSU represents a contingent right to receive one common share.
Open filing 0001771207-26-000002 Read from the filing’s XML Dispute this row
2025-12-12 Filed 2026-01-28Muller Lorenz Officer: Chief Commercial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Shares (100,000) — exercise price 1.74
Acquired (A)100,0000—100,000Direct (D) No
F6
  • F6 50% of the option will vest on June 12, 2026 and 50% will vest on December 12, 2026, subject to the Reporting Person continuing to provide service through each such date.
Open filing 0001771207-26-000002 Read from the filing’s XML Dispute this row
2025-12-12 Filed 2026-01-28Oliveto Joseph Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Shares
Acquired (A)280,000——583,721Direct (D) No
F1, F2
  • F1 Represents a performance stock unit (PSU) award that vested upon the certification by the Compensation Committee of the Board of Directors of the Issuer that the U.S. Food and Drug Administration has provided a New Drug Application Approval Letter granting approval of Cardamyst (etripamil).
  • F2 Each PSU represents a contingent right to receive one common share.
Open filing 0001437782-26-000004 Read from the filing’s XML Dispute this row
2025-12-12 Filed 2026-01-28Oliveto Joseph Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Shares (280,000) — exercise price 1.74
Acquired (A)280,0000—280,000Direct (D) No
F6
  • F6 50% of the option will vest on June 12, 2026 and 50% will vest on December 12, 2026, subject to the Reporting Person continuing to provide service through each such date.
Open filing 0001437782-26-000004 Read from the filing’s XML Dispute this row
2025-12-12 Filed 2026-01-28Hasija Amit Officer: CFO EVP of Corp. Development
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Shares
Acquired (A)100,000——150,000Direct (D) No
F1, F2
  • F1 Represents a performance stock unit (PSU) award that vested upon the certification by the Compensation Committee of the Board of Directors of the Issuer that the U.S. Food and Drug Administration has provided a New Drug Application Approval Letter granting approval of Cardamyst (etripamil).
  • F2 Each PSU represents a contingent right to receive one common share.
Open filing 0001787700-26-000002 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,925 filings read, the latest filed 2026-11-19. Prior quarter ending 2026-06-30: 9,176 filings read.

Showing 1–50 of 86

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Propel Bio Management, LLC Partly reported under another manager9,449,727 SH8,180,629 dollarsHigher by 2,020,137 Prior quarter: 7,429,590Open filing 0001829126-26-012373 Filed 2026-11-13 Dispute this row
Pavaki Capital Management LLC 9,337,848 SH8,083,775 dollarsHigher by 270,000 Prior quarter: 9,067,848Open filing 0002143027-26-000014 Filed 2026-10-26 Dispute this row
RTW INVESTMENTS, LP 7,833,336 SH6,781,319 dollarsUnchanged Prior quarter: 7,833,336Open filing 0001493215-26-000214 Filed 2026-11-16 Dispute this row
Point72 Asset Management, L.P. 5,467,247 SH4,732,996 dollarsHigher by 56,109 Prior quarter: 5,411,138Open filing 0000919574-26-008126 Filed 2026-11-16 Dispute this row
Simplify Asset Management Inc. 3,349,379 SH2,899,557 dollarsUnchanged Prior quarter: 3,349,379Open filing 0001172661-26-004722 Filed 2026-10-27 Dispute this row
MILLENNIUM MANAGEMENT LLC 2,235,274 SH1,935,077 dollarsLower by 906,945 Prior quarter: 3,142,219Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
TWO SIGMA INVESTMENTS, LP 1,721,021 SH1,489,888 dollarsLower by 318,994 Prior quarter: 2,040,015Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row
Kalehua Capital Management LLC 1,651,258 SH1,429,494 dollarsLower by 887,216 Prior quarter: 2,538,474Open filing 0002106181-26-000010 Filed 2026-11-13 Dispute this row
RVW Wealth, LLC 1,148,260 SH994,049 dollarsNot in the prior quarter’s filings read Open filing 0001756543-26-000005 Filed 2026-10-06 Dispute this row
MARSHALL WACE, LLP Partly reported under another manager1,117,642 SH972,350 dollarsLower by 680,053 Prior quarter: 1,797,695Open filing 0001318757-26-000012 Filed 2026-11-13 Dispute this row
Lion Point Capital, LP 820,000 SH709,874 dollarsUnchanged Prior quarter: 820,000Open filing 0001013594-26-001194 Filed 2026-11-16 Dispute this row
TORONTO DOMINION BANK 750,000 SH649,275 dollarsUnchanged Prior quarter: 750,000Open filing 0002052595-26-000123 Filed 2026-11-16 Dispute this row
Boxer Capital Management, LLC 666,666 SH577,132 dollarsUnchanged Prior quarter: 666,666Open filing 0001213900-26-120704 Filed 2026-11-16 Dispute this row
AMERIPRISE FINANCIAL INC Partly reported under another manager666,666 SH577,133 dollarsUnchanged Prior quarter: 666,666Open filing 0001193125-26-463125 Filed 2026-11-16 Dispute this row
MORGAN STANLEY Partly reported under another manager617,847 SH534,870 dollarsLower by 17,364 Prior quarter: 635,211Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
UBS Group AG Partly reported under another manager465,239 SH402,897 dollarsLower by 164 Prior quarter: 465,403Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Aptus Capital Advisors, LLC 405,000 SH350,609 dollarsHigher by 65,550 Prior quarter: 339,450Open filing 0001398344-26-020003 Filed 2026-11-13 Dispute this row
GUARDIAN WEALTH ADVISORS, LLC / NC 405,000 SH350,609 dollarsHigher by 65,550 Prior quarter: 339,450Open filing 0001398344-26-020133 Filed 2026-11-16 Dispute this row
LUMINUS MANAGEMENT LLC 275,000 SH238,068 dollarsNot in the prior quarter’s filings read Open filing 0001104659-26-128425 Filed 2026-11-16 Dispute this row
LPL Financial LLC 274,634 SH237,751 dollarsHigher by 53,761 Prior quarter: 220,873Open filing 0001403438-26-000005 Filed 2026-11-06 Dispute this row
JANE STREET GROUP, LLC Option: Call Partly reported under another manager213,100 SH184,481 dollarsHigher by 197,100 Prior quarter: 16,000Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
Wealthspire Advisors, LLC 159,500 SH138,080 dollarsHigher by 18,871 Prior quarter: 140,629Open filing 0001646247-26-000006 Filed 2026-11-13 Dispute this row
Valeo Financial Advisors, LLC Partly reported under another manager146,699 SH126,997 dollarsHigher by 16,000 Prior quarter: 130,699Open filing 0001722641-26-000006 Filed 2026-10-08 Dispute this row
CITADEL ADVISORS LLC Option: Call Partly reported under another manager120,100 SH103,971 dollarsHigher by 64,000 Prior quarter: 56,100Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
Virtu Financial LLC Partly reported under another manager113,848 SH99 dollarsHigher by 102,235 Prior quarter: 11,613Open filing 0001533964-26-000015 Filed 2026-11-17 Dispute this row
SIMPLEX TRADING, LLC Option: Call 113,000 SH97,824 dollarsHigher by 54,200 Prior quarter: 58,800Open filing 0001488542-26-000013 Filed 2026-11-04 Dispute this row
BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager110,918 SH96,022 dollarsLower by 62,786 Prior quarter: 173,704Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row
ADAR1 Capital Management, LLC 100,000 SH86,570 dollarsUnchanged Prior quarter: 100,000Open filing 0001940272-26-000033 Filed 2026-11-16 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Partly reported under another manager98,864 SH85,587 dollarsLower by 261,031 Prior quarter: 359,895Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
Cascades Capital Asset Management, LLC 83,610 SH104,513 dollarsUnchanged Prior quarter: 83,610Open filing 0001398344-26-020173 Filed 2026-11-16 Dispute this row
Pinnacle Wealth Planning Services, Inc. 79,070 SH68,451 dollarsNot in the prior quarter’s filings read Open filing 0001726752-26-000006 Filed 2026-10-27 Dispute this row
HRT FINANCIAL LP 66,528 SH57 dollarsNot in the prior quarter’s filings read Open filing 0001475597-26-000249 Filed 2026-11-13 Dispute this row
XTX Topco Ltd Partly reported under another manager62,565 SH54,163 dollarsHigher by 36,248 Prior quarter: 26,317Open filing 0001828301-26-000009 Filed 2026-11-16 Dispute this row
CITADEL ADVISORS LLC Option: Put Partly reported under another manager46,900 SH40,601 dollarsLower by 117,400 Prior quarter: 164,300Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
Waterloo Capital, L.P. 46,633 SH40,370 dollarsNot in the prior quarter’s filings read Open filing 0001104659-26-128557 Filed 2026-11-16 Dispute this row
October Effect Ltd 40,000 SH34,628 dollarsUnchanged Prior quarter: 40,000Open filing 0002078353-26-000004 Filed 2026-10-20 Dispute this row
Focus Partners Wealth 36,000 SH31,165 dollarsUnchanged Prior quarter: 36,000Open filing 0001542153-26-000021 Filed 2026-11-12 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager34,375 SH29,758 dollarsHigher by 1,488 Prior quarter: 32,887Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Option: Put Partly reported under another manager32,400 SH28,188 dollarsHigher by 9,800 Prior quarter: 22,600Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
Mariner, LLC 27,830 SH24,092 dollarsUnchanged Prior quarter: 27,830Open filing 0001580642-26-007648 Filed 2026-11-12 Dispute this row
STATE STREET CORP Partly reported under another manager27,238 SH23,580 dollarsHigher by 4,674 Prior quarter: 22,564Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
IMC-Chicago, LLC Option: Call 27,100 SH23,460 dollarsHigher by 3,900 Prior quarter: 23,200Open filing 0001452861-26-000007 Filed 2026-11-05 Dispute this row
Federation des caisses Desjardins du Quebec Partly reported under another manager26,805 SH23,209 dollarsLower by 2,976 Prior quarter: 29,781Open filing 0002022297-26-000010 Filed 2026-11-16 Dispute this row
RAYMOND JAMES FINANCIAL INC Partly reported under another manager26,600 SH23,028 dollarsLower by 3,470 Prior quarter: 30,070Open filing 0000720005-26-000081 Filed 2026-11-12 Dispute this row
GSA CAPITAL PARTNERS LLP 25,468 SH22 dollarsNot in the prior quarter’s filings read Open filing 0001362033-26-000013 Filed 2026-11-16 Dispute this row
Welch Forbes LLC 25,000 SH21,643 dollarsUnchanged Prior quarter: 25,000Open filing 0000105495-26-000005 Filed 2026-11-04 Dispute this row
JANE STREET GROUP, LLC Option: Put Partly reported under another manager24,300 SH21,037 dollarsLower by 6,900 Prior quarter: 31,200Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
NATIONAL BANK OF CANADA /FI/ Partly reported under another manager23,500 SH20,210 dollarsUnchanged Prior quarter: 23,500Open filing 0000926171-26-000014 Filed 2026-11-16 Dispute this row
Exit Wealth Advisors, LLC. Partly reported under another manager22,692 SH19,644 dollarsUnchanged Prior quarter: 22,692Open filing 0001765380-26-000494 Filed 2026-11-13 Dispute this row
Taylor Financial Group, Inc. 20,000 SH17,314 dollarsUnchanged Prior quarter: 20,000Open filing 0001172661-26-004800 Filed 2026-11-02 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • BOOTHBAY FUND MANAGEMENT, LLC 462,669 SH
  • Seven Fleet Capital Management LP 270,233 SH
  • Squarepoint Ops LLC 231,824 SH
  • Balyasny Asset Management L.P. 220,498 SH
  • TRU INDEPENDENCE ASSET MANAGEMENT 2, LLC 150,000 SH
  • Quadrature Capital Ltd 64,661 SH
  • Bay Rivers Group 46,633 SH
  • SG Americas Securities, LLC 45,574 SH
  • GEODE CAPITAL MANAGEMENT, LLC 40,789 SH
  • Tower Research Capital LLC (TRC) 24,185 SH
  • HighTower Advisors, LLC 20,000 SH
  • TWO SIGMA SECURITIES, LLC 16,745 SH
  • WINTON GROUP Ltd 14,300 SH
  • Safeguard Investment Advisory Group, LLC 12,406 SH
  • Eaton Financial Holdings Company, LLC 10,250 SH
  • Aptus Capital Advisors, LLC 500 SH
  • Medallion Wealth Advisors, LLC 340 SH
  • GROUP ONE TRADING LLC 224 SH
  • MERCER GLOBAL ADVISORS INC /ADV 123 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
RTW Investments, LP Common Shares, no par value per share9.912,356,953.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 7Open filing 0001493215-26-000112 Dispute this row
Roderick Wong Common Shares, no par value per share9.912,356,953.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 7Open filing 0001493215-26-000112 Dispute this row
Adage Capital Management, L.P. Common Shares, no par value6.378,000,000.0003/31/2026 Filed 2026-05-13SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-002920 Dispute this row
Robert Atchinson Common Shares, no par value6.378,000,000.0003/31/2026 Filed 2026-05-13SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-002920 Dispute this row
Phillip Gross Common Shares, no par value6.378,000,000.0003/31/2026 Filed 2026-05-13SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-002920 Dispute this row
Trails Edge Capital Partners, LP Common Shares4.35,333,333.0003/20/2026 Filed 2026-03-26SCHEDULE 13G/AAmendment 2Open filing 0001493152-26-013007 Dispute this row
Trails Edge Biotechnology Master Fund, LP Common Shares4.35,333,333.0003/20/2026 Filed 2026-03-26SCHEDULE 13G/AAmendment 2Open filing 0001493152-26-013007 Dispute this row
Ortav Yehudai Common Shares4.35,333,333.0003/20/2026 Filed 2026-03-26SCHEDULE 13G/AAmendment 2Open filing 0001493152-26-013007 Dispute this row
Pavaki Capital Management LLC Common Shares, no par value7.39,067,848.0012/31/2025 Filed 2026-08-07SCHEDULE 13GOpen filing 0002143027-26-000012 Dispute this row
Pavaki Capital Partners, LP Common Shares, no par value7.39,067,848.0012/31/2025 Filed 2026-08-07SCHEDULE 13GOpen filing 0002143027-26-000012 Dispute this row
Ashok Rambhai Patel Common Shares, no par value7.39,067,848.0012/31/2025 Filed 2026-08-07SCHEDULE 13GOpen filing 0002143027-26-000012 Dispute this row
RTW Investments, LP Common Shares, no par value per share9.99,155,168.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 6Open filing 0001493215-25-000045 Dispute this row
Roderick Wong Common Shares, no par value per share9.99,155,168.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 6Open filing 0001493215-25-000045 Dispute this row
Trails Edge Capital Partners, LP Common Shares9.99,017,880.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001493152-25-023424 Dispute this row
Trails Edge Biotechnology Master Fund, LP Common Shares9.99,017,880.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001493152-25-023424 Dispute this row
Ortav Yehudai Common Shares9.99,017,880.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001493152-25-023424 Dispute this row
Adage Capital Management, L.P. Common Shares, no par value9.998,659,064.0009/30/2025 Filed 2025-11-13SCHEDULE 13GOpen filing 0000902664-25-004894 Dispute this row
Robert Atchinson Common Shares, no par value9.998,659,064.0009/30/2025 Filed 2025-11-13SCHEDULE 13GOpen filing 0000902664-25-004894 Dispute this row
Phillip Gross Common Shares, no par value9.998,659,064.0009/30/2025 Filed 2025-11-13SCHEDULE 13GOpen filing 0000902664-25-004894 Dispute this row
Trails Edge Capital Partners, LP Common Shares9.98,847,882.0007/14/2025 Filed 2025-07-21SCHEDULE 13GOpen filing 0001641172-25-020404 Dispute this row
Trails Edge Biotechnology Master Fund, LP Common Shares9.98,847,882.0007/14/2025 Filed 2025-07-21SCHEDULE 13GOpen filing 0001641172-25-020404 Dispute this row
Ortav Yehudai Common Shares9.98,847,882.0007/14/2025 Filed 2025-07-21SCHEDULE 13GOpen filing 0001641172-25-020404 Dispute this row
Propel Bio Management, LLC Common Stock9.98,861,186.0007/11/2025 Filed 2025-12-23SCHEDULE 13GOpen filing 0001969764-25-000003 Dispute this row
Leen Kawas Common Stock9.98,861,186.0007/11/2025 Filed 2025-12-23SCHEDULE 13GOpen filing 0001969764-25-000003 Dispute this row
Richard Kayne Common Stock9.98,861,186.0007/11/2025 Filed 2025-12-23SCHEDULE 13GOpen filing 0001969764-25-000003 Dispute this row
Propel Bio Partners LLC Common Stock9.98,861,186.0007/11/2025 Filed 2025-12-23SCHEDULE 13GOpen filing 0001969764-25-000003 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,649,595 filings read, dated 2004-06-14 to 2026-11-19: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201566,682
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,123

Filings made before the SEC required XML are listed, not extracted.

Back to MILESTONE PHARMACEUTICALS INC.